##### Table of Contents



---

---

UNITED STATES SECURITIES AND
EXCHANGE COMMISSION

Washington, D.C. 20549




---



FORM 10-Q

(Mark One)

|      |                                                                                                                                                       
|----- | ------------------------------------------------------------------------------------------------------------------------------------------------------
|[X]   | Quarterly Report
Pursuant to Section 13 or 15(d) of the Securities Exchange Act
of 1934
For the quarterly period ended September 30, 2002             
|      |                                                                                                                                                       
|      | or                                                                                                                                                    
|      |                                                                                                                                                       
|[   ] | Transition Report
Pursuant to Section 13 or 15(d) of the Securities Exchange Act
of 1934
For the transition period from ____________ to ____________ .
|      |                                                                                                                                                       

Commission File Number 0-31499

EDEN Bioscience Corporation

(Exact name of registrant as specified in its charter)


|                                                                          |  |                                             
|------------------------------------------------------------------------- |  | --------------------------------------------
|Washington
(State or other jurisdiction of
incorporation or organization) |  | 91-1649604
(IRS Employer Identification No.)

3830 Monte Villa Parkway
Bothell, Washington 98021-6942
(Address of principal executive offices, including zip code)

(425) 806-7300
(Registrants telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports
required to be filed by Section 13 or 15(d) of the Securities Exchange Act of
1934 during the past 12 months (or for such shorter period that the registrant
was required to file such reports) and (2) has been subject to such filing
requirements for the past 90 days.
Yes [X] No [   ]

State the number of shares outstanding of each of the registrants classes of
common equity, as of the latest practicable date:

|                                     |  |                                              
|------------------------------------ |  | ---------------------------------------------
|Class
Common Stock, $.0025 Par Value |  | Outstanding as of November 4, 2002
24,307,495



---

---





---

TABLE OF CONTENTS



|                                      |                                                                                               |                                                                                        |  |  |  |  |  | 
|------------------------------------- | --------------------------------------------------------------------------------------------- | -------------------------------------------------------------------------------------- |  |  |  |  |  | 
|PART I  FINANCIAL INFORMATION       
|                                      | Item 1. Financial Statements                                                                 
|                                      |                                                                                               | CONDENSED CONSOLIDATED BALANCE SHEETS                                                 
|                                      |                                                                                               | CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS                                       
|                                      |                                                                                               | CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS                                       
|                                      |                                                                                               | NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS                        
|                                      | Item 2. Managements Discussion and Analysis of Financial Condition and Results of Operations
|                                      |                                                                                               | Factors That May Affect Our Business, Future Operating Fesults and Financial Condition
|                                      | Item 3. Quantitative and Qualitative Disclosures About Market Risk                           
|                                      | Item 4. Controls and Procedures                                                              
|PART II  OTHER INFORMATION          
|                                      | Item 2. Changes in Securities and Use of Proceeds                                            
|                                      | Item 6. Exhibits                                                                             
|SIGNATURES                           
|CHIEF EXECUTIVE OFFICER CERTIFICATION
|CHIEF FINANCIAL OFFICER CERTIFICATION
|EXHIBIT 99.1                         
|EXHIBIT 99.2                         



---



##### Table of Contents



EDEN Bioscience Corporation
Index to Form 10-Q

|               |  |                                                                                                                        |       |  |    |  |      |  | 
|-------------- |  | ---------------------------------------------------------------------------------------------------------------------- | ----- |  | -- |  | ---- |  | 
|               |  |                                                                                                                        |       |  |    |  | Page
|               |  |                                                                                                                        |       |  |    |  |     
|Part I         |  | Financial Information                                                                                                  |       |  |    | 
|Item 1         |  | Unaudited Financial Statements                                                                                         |       |  | 2  | 
|               |  | Condensed Consolidated Balance Sheets as of September 30, 2002 and December 31, 2001                                   |       |  | 2  | 
|               |  | Condensed Consolidated Statements of Operations for the Three Months and Nine Months Ended September 30, 2002 and 2001 |       |  | 3  | 
|               |  | Condensed Consolidated Statements of Cash Flows for the Nine Months Ended September 30, 2002 and 2001                  |       |  | 4  | 
|               |  | Notes to Unaudited Condensed Consolidated Financial Statements                                                         |       |  | 5  | 
|Item 2         |  | Management's Discussion and Analysis of Financial Condition and Results of Operations                                  |       |  | 8  | 
|               |  | Factors That May Affect Our Business, Future Operating Results and Financial Condition                                 |       |  | 14 | 
|Item 3         |  | Quantitative and Qualitative Disclosures About Market Risk                                                             |       |  | 21 | 
|Item 4         |  | Controls and Procedures                                                                                                |       |  | 21 | 
|Part II        |  | Other Information                                                                                                      |       |  |    | 
|Item 2         |  | Changes in Securities and Use of Proceeds                                                                              |       |  | 22 | 
|Item 6         |  | Exhibits                                                                                                               |       |  | 22 | 
|Signatures     |  |                                                                                                                        | 22    | 
|Certifications |  |                                                                                                                        | 23-24 | 

-1-



---



##### Table of Contents






PART I  FINANCIAL INFORMATION




Item 1. Financial Statements




EDEN BIOSCIENCE CORPORATION

CONDENSED CONSOLIDATED BALANCE SHEETS
(Unaudited)

ASSETS

|                                                  |                                                                                                                                                                                |                                            |            |               |            |              |            |             |            | 
|------------------------------------------------- | ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ | ------------------------------------------ | ---------- | ------------- | ---------- | ------------ | ---------- | ----------- | ---------- | 
|                                                  |                                                                                                                                                                                |                                            |            | September 30, |            | December 31,
|                                                  |                                                                                                                                                                                |                                            |            | 2002          |            | 2001        
|                                                  |                                                                                                                                                                                |                                            |            |               |            |             
|Current assets:                                   |                                                                                                                                                                                |                                            |            |               |            |              |            |            
|                                                  | Cash and cash equivalents                                                                                                                                                      |                                            | $          | 34,878,637    |            |              | $          | 48,327,022  |           
|                                                  | Accounts receivable                                                                                                                                                            |                                            |            | 164,653       |            |              |            | 89,128      |           
|                                                  | Inventory                                                                                                                                                                      |                                            |            | 2,249,362     |            |              |            | 2,117,953   |           
|                                                  | Other current assets                                                                                                                                                           |                                            |            | 544,253       |            |              |            | 897,825     |           
|                                                  |                                                                                                                                                                                |                                            |            |               |            |              |            |            
|                                                  |                                                                                                                                                                                | Total current assets                       |            |               | 37,836,905 |              |            |             | 51,431,928 | 
|Property and equipment, net                       |                                                                                                                                                                                |                                            | 20,336,059 |               |            |              | 22,385,662 |            
|Other assets                                      |                                                                                                                                                                                |                                            | 1,659,806  |               |            |              | 1,721,413  |            
|                                                  |                                                                                                                                                                                |                                            |            |               |            |              |            |            
|                                                  |                                                                                                                                                                                | Total assets                               |            | $             | 59,832,770 |              |            | $           | 75,539,003 | 
|                                                  |                                                                                                                                                                                |                                            |            |               |            |              |            |            
|LIABILITIES AND SHAREHOLDERS EQUITY             
|Current liabilities:                              |                                                                                                                                                                                |                                            |            |               |            |              |            |            
|                                                  | Accounts payable                                                                                                                                                               |                                            | $          | 275,149       |            |              | $          | 906,557     |           
|                                                  | Accrued liabilities                                                                                                                                                            |                                            |            | 3,817,587     |            |              |            | 4,019,396   |           
|                                                  | Current portion of capital lease obligations                                                                                                                                   |                                            |            | 137,605       |            |              |            | 216,452     |           
|                                                  |                                                                                                                                                                                |                                            |            |               |            |              |            |            
|                                                  |                                                                                                                                                                                | Total current liabilities                  |            |               | 4,230,341  |              |            |             | 5,142,405  | 
|Capital lease obligations, net of current portion |                                                                                                                                                                                |                                            | 36,098     |               |            |              | 129,916    |            
|Other long-term liabilities                       |                                                                                                                                                                                |                                            | 343,343    |               |            |              | 272,874    |            
|                                                  |                                                                                                                                                                                |                                            |            |               |            |              |            |            
|                                                  |                                                                                                                                                                                | Total liabilities                          |            |               | 4,609,782  |              |            |             | 5,545,195  | 
|                                                  |                                                                                                                                                                                |                                            |            |               |            |              |            |            
|Commitments and contingencies                     |                                                                                                                                                                                |                                            |            |               |            |              |            |            
|Shareholders equity:                             |                                                                                                                                                                                |                                            |            |               |            |              |            |            
|                                                  | Preferred stock, $.01 par value, 10,000,000 shares authorized; no shares
issued and outstanding at September 30, 2002 and December 31, 2001                                    |                                            |            |              |            |              |            |            |           
|                                                  | Common stock, $.0025 par value, 100,000,000 shares authorized; issued
and outstanding shares - 24,289,988 shares at September 30, 2002;
24,099,944 shares at December 31, 2001 |                                            |            | 60,725        |            |              |            | 60,250      |           
|                                                  | Additional paid-in capital                                                                                                                                                     |                                            |            | 132,442,265   |            |              |            | 132,326,759 |           
|                                                  | Deferred stock option compensation expense                                                                                                                                     |                                            |            | (2,540        | )          |              |            | (10,145     | )         
|                                                  | Cumulative translation adjustment                                                                                                                                              |                                            |            | (61,074       | )          |              |            | (33,577     | )         
|                                                  | Accumulated deficit                                                                                                                                                            |                                            |            | (77,216,388   | )          |              |            | (62,349,479 | )         
|                                                  |                                                                                                                                                                                |                                            |            |               |            |              |            |            
|                                                  |                                                                                                                                                                                | Total shareholders equity                 |            |               | 55,222,988 |              |            |             | 69,993,808 | 
|                                                  |                                                                                                                                                                                |                                            |            |               |            |              |            |            
|                                                  |                                                                                                                                                                                | Total liabilities and shareholders equity |            | $             | 59,832,770 |              |            | $           | 75,539,003 | 
|                                                  |                                                                                                                                                                                |                                            |            |               |            |              |            |            

The accompanying notes are an integral part of these statements.

-2-



---



##### Table of Contents






EDEN BIOSCIENCE CORPORATION

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(Unaudited)

|                                                                       |                                     |                          |            |                                  |            |                                 |            |           |            |      |             |           |             |   |             |           |             |  
|---------------------------------------------------------------------- | ----------------------------------- | ------------------------ | ---------- | -------------------------------- | ---------- | ------------------------------- | ---------- | --------- | ---------- | ---- | ----------- | --------- | ----------- | - | ----------- | --------- | ----------- | -
|                                                                       |                                     |                          |            | Three Months Ended September 30, |            | Nine Months Ended September 30,
|                                                                       |                                     |                          |            |                                  |            |                                
|                                                                       |                                     |                          |            | 2002                             |            | 2001                            |            | 2002      |            | 2001
|                                                                       |                                     |                          |            |                                  |            |                                 |            |           |            |     
|Product sales, net of sales
allowances                                 |                                     | $                        | 59,884     |                                  |            | $                               | 439,125    |           |            | $    | 1,687,420   |           |             | $ | 3,496,002   |          
|Operating expenses:                                                    |                                     |                          |            |                                  |            |                                 |            |           |            |      |             |           |             |   |             |          
|                                                                       | Cost of goods sold                  |                          |            | 373,591                          |            |                                 |            | 782,351   |            |      |             | 2,106,892 |             |   |             | 3,959,416 |            
|                                                                       | Research and development            |                          |            | 2,525,478                        |            |                                 |            | 3,645,357 |            |      |             | 8,139,694 |             |   |             | 9,329,530 |            
|                                                                       | Selling, general and administrative |                          |            | 1,939,977                        |            |                                 |            | 2,495,848 |            |      |             | 6,819,987 |             |   |             | 8,955,061 |            
|                                                                       |                                     |                          |            |                                  |            |                                 |            |           |            |      |             |           |             |   |             |          
|                                                                       |                                     | Total operating expenses |            |                                  | 4,839,046  |                                 |            |           | 6,923,556  |      |             |           | 17,066,573  |   |             |           | 22,244,007  |  
|                                                                       |                                     |                          |            |                                  |            |                                 |            |           |            |      |             |           |             |   |             |          
|                                                                       |                                     | Loss from operations     |            |                                  | (4,779,162 | )                               |            |           | (6,484,431 | )    |             |           | (15,379,153 | ) |             |           | (18,748,005 | )
|                                                                       |                                     |                          |            |                                  |            |                                 |            |           |            |      |             |           |             |   |             |          
|Other income (expense):                                                |                                     |                          |            |                                  |            |                                 |            |           |            |      |             |           |             |   |             |          
|                                                                       | Interest income                     |                          |            | 170,347                          |            |                                 |            | 585,341   |            |      |             | 582,994   |             |   |             | 2,556,004 |            
|                                                                       | Interest expense                    |                          |            | (7,940                           | )          |                                 |            | (19,331   | )          |      |             | (31,390   | )           |   |             | (66,716   | )          
|                                                                       | Loss on disposal of assets          |                          |            | (35,753                          | )          |                                 |            |          |            |      |             | (39,360   | )           |   |             |          |            
|                                                                       |                                     |                          |            |                                  |            |                                 |            |           |            |      |             |           |             |   |             |          
|                                                                       |                                     | Total other income       |            |                                  | 126,654    |                                 |            |           | 566,010    |      |             |           | 512,244     |   |             |           | 2,489,288   |  
|                                                                       |                                     |                          |            |                                  |            |                                 |            |           |            |      |             |           |             |   |             |          
|Loss before income taxes                                               |                                     |                          | (4,652,508 | )                                |            |                                 | (5,918,421 | )         |            |      | (14,866,909 | )         |             |   | (16,258,717 | )        
|Provision for income taxes                                             |                                     |                          |           |                                  |            |                                 |           |           |            |      |            |           |             |   |            |          
|                                                                       |                                     |                          |            |                                  |            |                                 |            |           |            |      |             |           |             |   |             |          
|Net loss                                                               |                                     | $                        | (4,652,508 | )                                |            | $                               | (5,918,421 | )         |            | $    | (14,866,909 | )         |             | $ | (16,258,717 | )        
|                                                                       |                                     |                          |            |                                  |            |                                 |            |           |            |      |             |           |             |   |             |          
|Basic and diluted net loss per share                                   |                                     | $                        | (0.19      | )                                |            | $                               | (0.25      | )         |            | $    | (0.61       | )         |             | $ | (0.68       | )        
|                                                                       |                                     |                          |            |                                  |            |                                 |            |           |            |      |             |           |             |   |             |          
|Weighted average shares outstanding
used to compute net loss per share |                                     |                          | 24,254,210 |                                  |            |                                 | 23,978,189 |           |            |      | 24,219,932  |           |             |   | 23,946,978  |          
|                                                                       |                                     |                          |            |                                  |            |                                 |            |           |            |      |             |           |             |   |             |          

The accompanying notes are an integral part of these statements.

-3-



---



##### Table of Contents






EDEN BIOSCIENCE CORPORATION

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited)

|                                                                       |                                                                         |                                                   |                                                     |             |                                 |             |             |             |            |             |  
|---------------------------------------------------------------------- | ----------------------------------------------------------------------- | ------------------------------------------------- | --------------------------------------------------- | ----------- | ------------------------------- | ----------- | ----------- | ----------- | ---------- | ----------- | -
|                                                                       |                                                                         |                                                   |                                                     |             | Nine Months Ended September 30,
|                                                                       |                                                                         |                                                   |                                                     |             |                                
|                                                                       |                                                                         |                                                   |                                                     |             | 2002                            |             | 2001       
|                                                                       |                                                                         |                                                   |                                                     |             |                                 |             |            
|Cash flows from operating activities:                                  |                                                                         |                                                   |                                                     |             |                                 |             |             |            
|                                                                       | Net loss                                                                |                                                   | $                                                   | (14,866,909 | )                               |             | $           | (16,258,717 | )         
|                                                                       | Adjustments to reconcile net loss to cash used in operating activities: |                                                   |                                                     |             |                                 |             |             |             |           
|                                                                       |                                                                         | Depreciation                                      |                                                     |             | 1,981,489                       |             |             |             | 1,138,319  |            
|                                                                       |                                                                         | Amortization of stock option compensation expense |                                                     |             | 7,605                           |             |             |             | 13,860     |            
|                                                                       |                                                                         | Loss (gain) on disposal of fixed assets           |                                                     |             | 39,360                          |             |             |             | (765       | )          
|                                                                       |                                                                         | Deferred rent payable                             |                                                     |             | 102,969                         |             |             |             | 206,051    |            
|                                                                       | Changes in assets and liabilities:                                      |                                                   |                                                     |             |                                 |             |             |             |           
|                                                                       |                                                                         | Accounts receivable                               |                                                     |             | (73,444                         | )           |             |             | 178,926    |            
|                                                                       |                                                                         | Inventory                                         |                                                     |             | 75,551                          |             |             |             | (811,316   | )          
|                                                                       |                                                                         | Other assets                                      |                                                     |             | 414,591                         |             |             |             | (2,207,865 | )          
|                                                                       |                                                                         | Accounts payable                                  |                                                     |             | (650,370                        | )           |             |             | (979,661   | )          
|                                                                       |                                                                         | Accrued liabilities                               |                                                     |             | (217,555                        | )           |             |             | 1,526,882  |            
|                                                                       |                                                                         | Other long-term liabilities                       |                                                     |             | (32,500                         | )           |             |             | 32,500     |            
|                                                                       |                                                                         |                                                   |                                                     |             |                                 |             |             |            
|                                                                       |                                                                         |                                                   | Net cash used in operating activities               |             |                                 | (13,219,213 | )           |             |            | (17,161,786 | )
|                                                                       |                                                                         |                                                   |                                                     |             |                                 |             |             |            
|Cash flows from investing activities:                                  |                                                                         |                                                   |                                                     |             |                                 |             |             |            
|                                                                       | Purchases of property and equipment                                     |                                                   |                                                     | (204,615    | )                               |             |             | (12,768,201 | )         
|                                                                       | Proceeds from disposal of equipment                                     |                                                   |                                                     | 24,473      |                                 |             |             | 2,733       |           
|                                                                       |                                                                         |                                                   |                                                     |             |                                 |             |             |            
|                                                                       |                                                                         |                                                   | Net cash used in investing activities               |             |                                 | (180,142    | )           |             |            | (12,765,468 | )
|                                                                       |                                                                         |                                                   |                                                     |             |                                 |             |             |            
|Cash flows from financing activities:                                  |                                                                         |                                                   |                                                     |             |                                 |             |             |            
|                                                                       | Reduction in capital lease obligations                                  |                                                   |                                                     | (172,665    | )                               |             |             | (189,844    | )         
|                                                                       | Proceeds from issuance of common stock                                  |                                                   |                                                     | 115,981     |                                 |             |             | 290,342     |           
|                                                                       |                                                                         |                                                   |                                                     |             |                                 |             |             |            
|                                                                       |                                                                         |                                                   | Net cash provided by (used in) financing activities |             |                                 | (56,684     | )           |             |            | 100,498     |  
|                                                                       |                                                                         |                                                   |                                                     |             |                                 |             |             |            
|Effect of foreign currency exchange rates on cash and cash equivalents |                                                                         |                                                   | 7,654                                               |             |                                 |             | (19,226     | )          
|                                                                       |                                                                         |                                                   |                                                     |             |                                 |             |             |            
|Net decrease in cash and cash equivalents                              |                                                                         |                                                   | (13,448,385                                         | )           |                                 |             | (29,845,982 | )          
|Cash and cash equivalents at beginning of period                       |                                                                         |                                                   | 48,327,022                                          |             |                                 |             | 86,556,865  |            
|                                                                       |                                                                         |                                                   |                                                     |             |                                 |             |             |            
|Cash and cash equivalents at end of period                             |                                                                         | $                                                 | 34,878,637                                          |             |                                 | $           | 56,710,883  |            
|                                                                       |                                                                         |                                                   |                                                     |             |                                 |             |             |            
|Supplemental disclosures:                                              |                                                                         |                                                   |                                                     |             |                                 |             |             |            
|                                                                       | Cash paid for interest                                                  |                                                   | $                                                   | 31,390      |                                 |             | $           | 66,716      |           
|                                                                       | Accrued liabilities for construction in process                         |                                                   |                                                     |            |                                 |             |             | 2,287,540   |           
|                                                                       | Depreciation charges capitalized into inventory                         |                                                   |                                                     | 208,225     |                                 |             |             | 265,703     |           

The accompanying notes are an integral part of these statements.

-4-



---



##### Table of Contents






EDEN BIOSCIENCE CORPORATION

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

1. Organization and Summary of Significant Accounting Policies

Organization and Business

EDEN Bioscience Corporation (the Company) was incorporated in the State
of Washington on July 18, 1994. The Company is a plant technology company
focused on developing, manufacturing and marketing innovative, natural
protein-based products for agriculture and began sales of its initial product,
Messenger®, in August 2000.

Basis of Presentation

The accompanying unaudited condensed consolidated financial statements
have been prepared in accordance with generally accepted accounting principles
for interim financial information and pursuant to the instructions to Form
10-Q. Accordingly, they do not include all of the information and footnotes
required by generally accepted accounting principles for complete financial
statements. The balance sheet at December 31, 2001 has been derived from the
audited financial statements at that date but does not include all of the
information and footnotes required by generally accepted accounting principles
for complete financial statements. These financial statements and notes should
be read in conjunction with the financial statements and notes for the year
ended December 31, 2001 included in the Companys Annual Report on Form 10-K,
which was filed with the Securities and Exchange Commission on March 29, 2002.

In the opinion of management, the unaudited condensed consolidated
financial statements include all adjustments, consisting only of normal
recurring adjustments, necessary to state fairly the financial information set
forth therein. Results of operations for the three months and nine months ended
September 30, 2002 are not necessarily indicative of the results expected for
the full fiscal year or for any future period.

Use of Estimates

The preparation of financial statements in conformity with generally
accepted accounting principles requires management to make estimates and
assumptions that affect the reported amounts of assets and liabilities and the
disclosure of contingent assets and liabilities at the date of the financial
statements and the reported amounts of revenue and expenses during the
reporting period. Examples include depreciable lives of property and equipment,
expense accruals and provisions for sales allowances, warranty claims,
inventory valuation and bad debts. Such estimates and assumptions are based on
historical experience, where applicable, and other assumptions that the Company
believes are reasonable under the circumstances. We periodically review
estimates and assumptions and the effects of revisions are reflected in the
consolidated financial statements in the period they are determined to be
necessary. Actual results could differ from these estimates.

Property and Equipment

Equipment and leasehold improvements are stated at historical cost.
Improvements and replacements are capitalized. Maintenance and repairs are
expensed when incurred. The provision for depreciation is determined using
straight-line and accelerated methods, which allocate costs over estimated
useful lives of one to 20 years. On January 1, 2001, the Company adopted the
units-of-production method of depreciation for manufacturing equipment placed
into service after that date. Equipment leased under capital leases is
depreciated over the shorter of the equipments estimated useful life or lease
term, which ranges between three to five years.

Revenue

The Company recognizes revenue from product sales, net of sales
allowances, when product is delivered to distributors and all significant
obligations of the Company have been satisfied, unless acceptance provisions or
other contingencies exist. If acceptance provisions or contingencies exist,
revenue is recognized after such provisions or contingencies have been
satisfied. Distributors do not have price protection or product return rights.
The Company provides an allowance for warranty claims based on reasonable
expectations. Shipping and handling costs related to product sales that are
paid by the Company are included in cost of goods sold.

-5-



---



##### Table of Contents



EDEN BIOSCIENCE CORPORATION

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)

Sales allowances represent allowances granted to independent distributors
for sales and marketing support, product warehousing and delivery and
information exchange and are based on a percentage of sales. Sales allowances
are estimated and accrued when the related product sales revenue is recognized
and are paid to distributors when the distributors sell the product and report
the sales data to the Company, usually on a quarterly basis. Gross product
sales and sales allowances are as follows:

|                    |                                        |   |                    |        |                   |   |          |         |      |   |           |           |  |   |            |           | 
|------------------- | -------------------------------------- | - | ------------------ | ------ | ----------------- | - | -------- | ------- | ---- | - | --------- | --------- |  | - | ---------- | --------- | 
|                    |                                        |   | Three Months Ended |        | Nine Months Ended
|                    |                                        |   | September 30,      |        | September 30,    
|                    |                                        |   |                    |        |                  
|                    |                                        |   | 2002               |        | 2001              |   | 2002     |         | 2001
|                    |                                        |   |                    |        |                   |   |          |         |     
|Gross product sales |                                        | $ | 65,239             |        |                   | $ | 644,299  |         |      | $ | 2,166,160 |           |  | $ | 5,360,737  |          
|Sales allowances    |                                        |   | (5,355             | )      |                   |   | (205,174 | )       |      |   | (478,740  | )         |  |   | (1,864,735 | )        
|                    |                                        |   |                    |        |                   |   |          |         |      |   |           |           |  |   |            |          
|                    | Product sales, net of sales allowances |   | $                  | 59,884 |                   |   | $        | 439,125 |      |   | $         | 1,687,420 |  |   | $          | 3,496,002 | 
|                    |                                        |   |                    |        |                   |   |          |         |      |   |           |           |  |   |            |          

Net Loss Per Share

Basic net loss per share is calculated as the net loss divided by the
weighted average number of common shares outstanding during the period. Diluted
net loss per share is calculated as the net loss divided by the sum of the
weighted average number of common shares outstanding during the period plus the
additional common shares that would have been issued had all dilutive warrants
and options been exercised, less shares that would be repurchased with the
proceeds from such exercises (treasury stock method). The effect of including
outstanding options and warrants is antidilutive for all periods presented.
Therefore, options and warrants have been excluded from the calculation of
diluted net loss per share and consist of the following:

|                                  |  |                     |           |      |  |  |           | 
|--------------------------------- |  | ------------------- | --------- | ---- |  |  | --------- | 
|                                  |  | As of September 30,
|                                  |  |                    
|                                  |  | 2002                |           | 2001
|                                  |  |                     |           |     
|Options to purchase common stock  |  |                     | 2,124,452 |      |  |  | 2,675,737 | 
|Warrants to purchase common stock |  |                     | 260,805   |      |  |  | 290,805   | 

Comprehensive Loss

The following table summarizes the Companys comprehensive loss for the
three months and nine months ended September 30, 2002 and 2001:

|                                  |                          |   |                    |            |                   |   |            |            |      |   |             |             |   |   |             |             |  
|--------------------------------- | ------------------------ | - | ------------------ | ---------- | ----------------- | - | ---------- | ---------- | ---- | - | ----------- | ----------- | - | - | ----------- | ----------- | -
|                                  |                          |   | Three Months Ended |            | Nine Months Ended
|                                  |                          |   | September 30,      |            | September 30,    
|                                  |                          |   |                    |            |                  
|                                  |                          |   | 2002               |            | 2001              |   | 2002       |            | 2001
|                                  |                          |   |                    |            |                   |   |            |            |     
|Net loss                          |                          | $ | (4,652,508         | )          |                   | $ | (5,918,421 | )          |      | $ | (14,866,909 | )           |   | $ | (16,258,717 | )          
|Cumulative translation
adjustment |                          |   | (16,941            | )          |                   |   | (5,538     | )          |      |   | (27,497     | )           |   |   | (23,687     | )          
|                                  |                          |   |                    |            |                   |   |            |            |      |   |             |             |   |   |             |            
|                                  | Total comprehensive loss |   | $                  | (4,669,449 | )                 |   | $          | (5,923,959 | )    |   | $           | (14,894,406 | ) |   | $           | (16,282,404 | )
|                                  |                          |   |                    |            |                   |   |            |            |      |   |             |             |   |   |             |            

Reclassifications

Certain reclassifications have been made in prior years financial
statements to conform to classifications used in the current year.

2. Inventory

Inventory, at average cost, consists of the following:

|                |                 |   |               |           |              |   |           |           | 
|--------------- | --------------- | - | ------------- | --------- | ------------ | - | --------- | --------- | 
|                |                 |   | September 30, |           | December 31,
|                |                 |   | 2002          |           | 2001        
|                |                 |   |               |           |             
|Raw materials   |                 | $ | 857,755       |           |              | $ | 934,824   |          
|Work in process |                 |   | 291,118       |           |              |   | 82,069    |          
|Finished goods  |                 |   | 1,100,489     |           |              |   | 1,101,060 |          
|                |                 |   |               |           |              |   |           |          
|                | Total inventory |   | $             | 2,249,362 |              |   | $         | 2,117,953 | 
|                |                 |   |               |           |              |   |           |          

-6-



---



##### Table of Contents



EDEN BIOSCIENCE CORPORATION

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)

3. Property and Equipment

Property and equipment, at cost, consist of the following:

|                               |                            |   |               |            |              |   |            |            | 
|------------------------------ | -------------------------- | - | ------------- | ---------- | ------------ | - | ---------- | ---------- | 
|                               |                            |   | September 30, |            | December 31,
|                               |                            |   | 2002          |            | 2001        
|                               |                            |   |               |            |             
|Equipment                      |                            | $ | 13,101,971    |            |              | $ | 12,986,850 |           
|Equipment under capital leases |                            |   | 512,742       |            |              |   | 714,626    |           
|Leasehold improvements         |                            |   | 12,572,529    |            |              |   | 12,486,376 |           
|                               |                            |   |               |            |              |   |            |           
|                               |                            |   | 26,187,242    |            |              |   | 26,187,852 |           
|Less accumulated depreciation  |                            |   | (5,851,183    | )          |              |   | (3,802,190 | )         
|                               |                            |   |               |            |              |   |            |           
|                               | Net property and equipment |   | $             | 20,336,059 |              |   | $          | 22,385,662 | 
|                               |                            |   |               |            |              |   |            |           

The Company recorded depreciation of $676,862 and $520,761 for the three
months ended September 30, 2002 and 2001, respectively, and $2,189,714 and
$1,404,022 for the nine months ended September 30, 2002 and 2001, respectively.

4. Accrued Liabilities

Accrued liabilities consist of the following:

|                                              |                           |   |               |           |              |   |           |           | 
|--------------------------------------------- | ------------------------- | - | ------------- | --------- | ------------ | - | --------- | --------- | 
|                                              |                           |   | September 30, |           | December 31,
|                                              |                           |   | 2002          |           | 2001        
|                                              |                           |   |               |           |             
|Sales allowances and marketing expenses       |                           | $ | 1,226,583     |           |              | $ | 389,775   |          
|Compensation and benefits                     |                           |   | 1,004,322     |           |              |   | 1,397,639 |          
|Research and development field trial expenses |                           |   | 490,968       |           |              |   | 1,113,546 |          
|Deferred revenue                              |                           |   | 308,952       |           |              |   | 52,283    |          
|Warranty                                      |                           |   | 268,861       |           |              |   | 324,249   |          
|Patent costs                                  |                           |   | 167,388       |           |              |   | 204,885   |          
|Insurance premiums                            |                           |   |              |           |              |   | 342,320   |          
|Other                                         |                           |   | 350,513       |           |              |   | 194,699   |          
|                                              |                           |   |               |           |              |   |           |          
|                                              | Total accrued liabilities |   | $             | 3,817,587 |              |   | $         | 4,019,396 | 
|                                              |                           |   |               |           |              |   |           |          

5. Stock Options and Warrants

The following table summarizes stock option activity since December 31,
2001:

|                              |                   |  |           |            |  
|----------------------------- | ----------------- |  | --------- | ---------- | -
|                              |                   |  | Number of
|                              |                   |  | Options  
|                              |                   |  |          
|Balance at December 31, 2001  |                   |  | 2,740,603 |           
|                              | Options granted   |  |           | 676,000    |  
|                              | Options cancelled |  |           | (1,049,485 | )
|                              | Options exercised |  |           | (242,666   | )
|                              |                   |  |           |           
|Balance at September 30, 2002 |                   |  | 2,124,452 |           
|                              |                   |  |           |           

The Company has elected to apply the disclosure-only provisions of
Statement of Financial Accounting Standards (SFAS) No. 123, Accounting for
Stock-Based Compensation. Accordingly, the Company accounts for stock-based
compensation using the intrinsic value method prescribed in Accounting
Principles Board Opinion No. 25, Accounting for Stock Issued to Employees,
and related interpretations.

On June 17, 2002, the Company offered to exchange certain outstanding
options to purchase shares of its common stock granted to its current U.S.
employees and officers (other than its Chief Financial Officer and
then-Interim President) under the EDEN Bioscience Corporation 1995
Combined Incentive and Nonqualified Stock Option Plan (the 1995 Plan) and the
EDEN Bioscience Corporation 2000 Stock Incentive Plan (the 2000 Plan and,
together with the 1995 Plan, the Stock Option Plans) for new options it will
grant under the 2000 Plan. The offer expired on July 17, 2002, at which time
the Company cancelled options to purchase 788,900 shares of its common stock
that were tendered for exchange or cancellation without replacement. Under the
terms and subject to the conditions of the offer, the Company expects to grant
new options to purchase approximately 578,200 shares of its common stock on or
about January 20, 2003, the date that is at least six months and one day after
the date that the Company cancelled the tendered options, subject to new option
agreements to be executed by the Company and its employees who participated in
the offer. Each new option will have an exercise price equal to the fair market
value

-7-



---



##### Table of Contents



EDEN BIOSCIENCE CORPORATION

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)

of the Companys common stock on the new grant date and will vest over
four years at a rate of 25% on each anniversary of the vesting start date of
the tendered option that it replaces.

As of September 30, 2002, the Company had warrants outstanding to purchase
260,805 shares of its common stock. No warrants to purchase shares of the
Companys common stock were issued during the nine-month period ended September
30, 2002.

6. Major Customers

Net sales revenue for the nine months ended September 30, 2002 resulted
from sales to 24 distributors, three of which accounted for an aggregate of 33%
of net sales revenue. One of these distributors, AG Rx, Inc., accounted for
$195,000 (12%) of net sales revenue. Helena Chemical Company accounted for
$191,200 (11%) of net sales revenue and Triangle Chemical Company, Inc.
accounted for $164,700 (10%) of net sales revenue.

Net sales revenue for the nine months ended September 30, 2001 resulted
from sales to seven distributors, two of which accounted for an aggregate of
83% of net sales revenue. Sales to United Agri Products, a subsidiary of
ConAgra Foods, Inc., accounted for $2.5 million (71%) of net sales revenue and
sales to Western Farm Service accounted for $420,300 (12%) of net sales
revenue.

7. Restructuring Charges and Other Costs

The Company recorded restructuring costs of $273,342 for severance and
other costs associated with workforce reductions in the quarter ended June 30,
2002. These costs are recorded in the consolidated statements of operations as
a component of research and development expense or selling, general and
administrative expense, depending upon the classification of the affected
employees. Of the 20 employees included in the workforce reduction, 14 worked
in research and development and the remainder worked in a variety of other
areas. Although the Companys restructuring plan was executed by June 30, 2002,
payment of certain restructuring costs will continue through the end of 2002.
Restructuring costs are summarized as follows:

|     |  |         |         |          |  |          |   |                    |  |   |         |  |  |   |        | 
|---- |  | ------- | ------- | -------- |  | -------- | - | ------------------ |  | - | ------- |  |  | - | ------ | 
|     |  | Total   |         | Non-Cash |  | Cash     |   | Liability at      
|     |  | Charges |         | Charges  |  | Payments |   | September 30, 2002
|     |  |         |         |          |  |          |   |                   
|2002 |  | $       | 273,342 |          |  | $        |  |                    |  | $ | 221,012 |  |  | $ | 52,330 | 




Item 2. Managements Discussion and Analysis of Financial Condition and Results of Operations

This discussion and analysis should be read in conjunction with our
unaudited condensed consolidated financial statements and accompanying notes
thereto included in this report and with the 2001 audited financial statements
and notes thereto included in our Annual Report on Form 10-K, which was filed
with the Securities and Exchange Commission on March 29, 2002.

The following discussion of our financial condition and results of
operations contains forward-looking statements that involve risks and
uncertainties, such as statements of our plans, objectives, expectations and
intentions. We use words such as anticipate, believe, expect, future
and intend and similar expressions to identify forward-looking statements.
However, these words are not the exclusive means of identifying such
statements. In addition, any statements that refer to expectations, projections
or other characterizations of future events or circumstances are
forward-looking statements. Our actual results could differ materially from
those anticipated in these forward-looking statements for many reasons,
including the factors described below and under the caption Factors That May
Affect Our Business, Future Operating Results and Financial Condition set
forth at the end of this Item 2. You should not place undue reliance on these
forward-looking statements, which apply only as of the date of this Form 10-Q.
The cautionary statements made in this report should be read as being
applicable to all forward-looking statements wherever they appear in this
report.

Overview

We are a plant technology company focused on developing, manufacturing and
marketing innovative, natural protein-based products for agriculture. We have a
fundamentally new, patented and proprietary technology that we believe will
improve crop production and plant protection worldwide. We believe our
technology and initial product,

-8-



---



##### Table of Contents



Messenger, offer innovative solutions versus traditional plant protection
and crop enhancement alternatives and, importantly, avoid the substantial and
growing public resistance to chemical pesticides and gene-based biotechnology.
Commercial sales of Messenger began in August 2000.

We have incurred significant operating losses since inception. As of
September 30, 2002, we had an accumulated deficit of $77.2 million. We incurred
net losses of $4.7 million and $5.9 million for the quarters ended
September 30, 2002 and 2001, respectively. The net loss for the nine
months ended September 30, 2002 was
$14.9 million, compared to a loss of $16.3 million for the nine months
ended September 30, 2001. We expect to incur additional net losses as we
proceed with the commercialization of Messenger and the development of new
products and technologies.

Results of Operations

Three Months and Nine Months Ended September 30, 2002 and 2001

Revenue

We recognize revenue from product sales when (a) the product is delivered
to independent distributors, (b) we have satisfied all of our significant
obligations and (c) any acceptance provisions or other contingencies have been
satisfied. We do not offer price protection or product return rights to our
distributors. We generated our first product sales revenue in August 2000. All
product sales revenue to date has resulted from sales of Messenger, our only
product, to distributors primarily in the United States. Product sales revenue
is reported net of applicable sales allowances, as follows:

|                    |                                        |   |                     |    |                     |   |      |     |      |   |       |       |  |   |        |       | 
|------------------- | -------------------------------------- | - | ------------------- | -- | ------------------- | - | ---- | --- | ---- | - | ----- | ----- |  | - | ------ | ----- | 
|                    |                                        |   | Three Months        |    | Nine Months        
|                    |                                        |   | Ended September 30, |    | Ended September 30,
|                    |                                        |   |                     |    |                    
|                    |                                        |   | 2002                |    | 2001                |   | 2002 |     | 2001
|                    |                                        |   |                     |    |                     |   |      |     |     
|                    |                                        |   | (in thousands)      |    | (in thousands)     
|Gross product sales |                                        | $ | 65                  |    |                     | $ | 644  |     |      | $ | 2,166 |       |  | $ | 5,361  |      
|Sales allowances    |                                        |   | (5                  | )  |                     |   | (205 | )   |      |   | (479  | )     |  |   | (1,865 | )    
|                    |                                        |   |                     |    |                     |   |      |     |      |   |       |       |  |   |        |      
|                    | Product sales, net of sales allowances |   | $                   | 60 |                     |   | $    | 439 |      |   | $     | 1,687 |  |   | $      | 3,496 | 
|                    |                                        |   |                     |    |                     |   |      |     |      |   |       |       |  |   |        |      

Gross product sales revenue for the third quarter of 2002 was $65,200, a
decrease of $579,100 (90%) from $644,300 in the comparable quarter of 2001.
Gross product sales revenue for the first nine months of the year totaled $2.2
million, a decrease of $3.2 million (59%) from $5.4 million for the same period
in 2001. Sales in the first nine months of 2002 were made to 24 distributors,
three of which accounted for an aggregate of 33% of net sales revenue. One of
these distributors, AG Rx, Inc., accounted for $195,000 (12%) of net sales
revenue. Helena Chemical Company accounted for $191,200 (11%) of net sales
revenue and Triangle Chemical Company, Inc. accounted for $164,700 (10%) of net
sales revenue.

Foreign sales to customers in Europe and Central America totaled $42,000
in the three months ended September 30, 2002, or 64% of gross sales for the
quarter, and $64,400 in the nine months ended September 30, 2002, or 3% of
gross sales for that period. No foreign sales were recorded in the nine months
ended September 30, 2001.

Some of our major distributors in the United States, particularly in our
Southern region, currently hold significant inventories of Messenger. In 2000,
we shipped approximately 453,000 ounces of Messenger to our U.S. distributors.
We estimate that approximately 66,000 ounces were sold by our distributors to
growers in 2000 and approximately 387,000 ounces remained in distributors
inventories at December 31, 2000. In 2001, we shipped approximately 1,225,000
ounces of Messenger to our U.S. distributors. We estimate that approximately
596,000 ounces were sold by our distributors to growers in 2001 and
approximately 1,016,000 ounces remained in distributors inventories at
December 31, 2001. In the first nine months of 2002, we shipped approximately
477,000 ounces of Messenger to our U.S. distributors. We estimate that
approximately 611,000 ounces were sold by our distributors to growers in the
first nine months of 2002 and that approximately 882,000 ounces remained in
distributors inventories at September 30, 2002. We do not expect distributors
that have significant inventories of Messenger to place additional orders for
Messenger until their current inventories are reduced and, therefore, we expect
sales to distributors in the next quarter to be minor. We are working with our
distributors and growers to reduce distributors inventories of Messenger.

-9-



---



##### Table of Contents



Sales Allowances

Sales allowances represent allowances granted to independent distributors
for sales and marketing support, product warehousing and delivery and
information exchange and are based on a percentage of sales. Sales allowances
are accrued when the related product sales revenue is recognized and are paid
to distributors when the distributors sell the product and report the sales
data to us, usually on a quarterly basis. Sales allowances were $5,400 (8% of
gross product sales) for the third quarter of 2002 and $205,000 (32% of gross
product sales) in the comparable quarter of 2001. Sales allowances for the
first nine months of the year totaled $478,700 (22% of gross product sales) in
2002 and $1.9 million (35% of gross product sales) in 2001. Sales allowances as
a percentage of gross product sales have declined as we have increased the
number of distributors and diversified the outlets through which our product is
sold. Sales allowances also declined in the three months and nine months ended
September 30, 2002 due to increased foreign sales, for which no sales
allowance is typically owed. We expect 2002 sales allowances to average
approximately 20-25% of gross product sales. Actual sales allowances paid may
be higher or lower than the estimate accrued, depending upon the level of
service provided by the distributor.

Cost of Goods Sold

Cost of goods sold consists primarily of the cost of Messenger sold to
distributors, idle capacity charges and the cost of Messenger used for
promotional purposes. Cost of goods sold was $373,600 in the third quarter of
2002 compared to $782,400 in the third quarter of 2001. This reduction resulted
primarily from steps taken earlier in the year to reduce staffing and other
manufacturing overhead costs during periods of non-production and from a
reduction in net sales. Idle capacity charges for the quarter ended September
30, 2002 were down by $226,000 from the same quarter last year. We expect to
incur idle capacity charges in the future and will continue to take steps to
minimize such costs.

For the first nine months of 2002, cost of goods sold was $2.1 million,
compared to $4.0 million for the same period in 2001. This decrease was due
primarily to an approximate $1.4 million write-down of inventory recorded in
the second quarter of 2001, consisting primarily of bulk Messenger product,
that resulted from the following circumstances: inventory levels that exceeded
our revenue forecasts; an expectation that we would change our product
formulation within the revenue forecast period; and disposal of bulk Messenger
that did not meet our highest standards as a result of a change, since
rectified, in the manufacturing process at our new facility. Also, the
reduction in gross sales for the nine months ended September 30, 2002
contributed to a decrease of $706,000 in cost of goods sold for the period.
These reductions were offset by increases in other components of cost of goods
sold, principally an increase of $421,900 in Messenger distributed for
promotional purposes.

Research and Development Expenses

Research and development expenses consist primarily of personnel, field
trial, laboratory, patent and facility expenses. Research and development
expenses decreased $1.1 million (31%) from $3.6 million in the third quarter of
2001 to $2.5 million in the same quarter of 2002. For the first nine months of
2002, research and development costs were $8.1 million, a decrease of $1.2
million (13%) from $9.3 million in the same period last year. These decreases
were primarily due to lower spending on personnel costs, field trials, patents
and trademarks, research supplies and travel, offset by increases in
depreciation and facility costs. Compared to the second quarter of this year,
company-wide research and development costs in the third quarter were lower by
7%. We expect research and development costs to continue to decrease as we
re-focus our research and development efforts in the United States and scale
back such efforts in Europe.

Selling, General and Administrative Expenses

Selling, general and administrative expenses consist of payroll and
related expenses for sales and marketing, executive and administrative
personnel; advertising, marketing and professional fees; and other corporate
expenses. Selling, general and administrative expenses decreased $555,900 (22%)
from $2.5 million in the third quarter of 2001 to $1.9 million in the same
quarter of 2002. For the first nine months of 2002, selling, general and
administrative expenses were $6.8 million, a decrease of $2.2 million (24%)
from $9.0 million in the same period last year. The majority of the decreases
occurred in the United States and resulted primarily from reductions in
advertising and marketing, travel and personnel costs, offset by increases in
insurance, consultant, depreciation and facility costs. Compared to the second
quarter of this year, company-wide selling, general and administrative costs in
the third quarter were lower by 12%. We expect these costs to decrease for the
remainder of the year as the growing season ends.

-10-



---



##### Table of Contents



In an effort to reduce facility and related costs going forward, we have
begun to market excess laboratory and office space at our headquarters in
Bothell, Washington. If we are successful in finding a qualified subtenant and
negotiating a sublease agreement, the market lease rate is not likely to cover
all of the unamortized costs of leasehold improvements and equipment related to
the subleased space. While it is not possible at this time to estimate the
amount of a shortfall, the write-off of these fixed assets would likely have a
material adverse impact on our results of operations for the quarter and year
in which the charge is recorded. At September 30, 2002, the estimated net book
value of leasehold improvements and equipment in the space being marketed for
sublease was approximately $4.6 million.

Interest Income

Interest income consists of earnings on our cash and cash equivalents.
Interest income decreased $415,000 (71%) from $585,300 in the third quarter of
2001 to $170,300 in the same quarter of 2002. For the first nine months of
2002, interest income was $583,000, down $2.0 million (77%) from $2.6 million
in the same period last year. These decreases were due primarily to
significantly lower average cash balances available for investment in the
current year and significant interest rate reductions that have occurred in the
last year.

Interest Expense

Interest expense consists of interest we pay on capital leases used to
finance certain equipment purchases. Interest expense decreased $11,400 (59%)
from $19,300 in the third quarter of 2001 to $7,900 in the same quarter of
2002. For the first nine months of 2002, interest expense was $31,400, down
$35,300 (53%) from $66,700 in the same period last year. These decreases were
due to reduced leasing activity and lower average principal balances as we pay
down our existing capital lease obligations.

Income Taxes

We have generated a net loss from operations in each period since we began
doing business. As of
December 31, 2001, we had accumulated approximately $62 million of net
operating loss carryforwards for federal income tax purposes. These
carryforwards expire between 2009 and 2021. The annual use of these net
operating loss carryforwards may be limited in the event of a cumulative change
in ownership of more than 50%.

Liquidity and Capital Resources

At September 30, 2002, our cash and cash equivalents totaled $34.9
million, a decrease of $13.4 million from the balance at December 31, 2001.
Prior to October 2000, we financed our operations primarily through the private
sale of our equity securities, resulting in net proceeds of approximately $36.5
million through September 30, 2000. In October 2000, we received approximately
$91.5 million in net proceeds from the initial public offering of 6,670,000
shares of our common stock. To a lesser extent, we have financed our equipment
purchases through lease financings.

Net cash used in operations decreased $4.0 million (23%) from $17.2
million in the first nine months of 2001 to $13.2 million in the same period of
2002. Net cash used in operations in the first nine months of 2002 resulted
primarily from a net loss of $12.9 million, after adding back depreciation
expense of $2.0 million, and fluctuations in various asset and liability
balances totaling $483,700. We expect that cash expenditures on operations will
continue to be significant.

Net cash used in investing activities decreased $12.6 million (98%) from
$12.8 million in the first nine months of 2001 to $180,100 in the same period
of 2002. Investing activities in the first nine months of 2001 consisted
primarily of property and equipment purchases in connection with expansion of
our manufacturing and research and development facilities, which was completed
by December 31, 2001.

Net cash used in financing activities increased $157,200 (156%) from
$100,500 cash provided in the first nine months of 2001 to $56,700 used in the
same period of 2002. The primary use of funds in both periods was to pay down
principal on our outstanding capital leases, offset by proceeds from the
issuance of common stock of $116,000 in 2002 and $290,000 in 2001.

We conduct our operations in three primary functional currencies: the
U.S. dollar, the European Union euro and the Mexican peso. Historically,
neither fluctuations in foreign exchange rates nor changes in foreign economic

-11-



---



##### Table of Contents



conditions have had a significant impact on our financial condition or
results of operations. We currently do not hedge our foreign currency exposures
and are therefore subject to the risk of exchange rate fluctuations. We may
invoice our international customers in U.S. dollars, euros and Mexican pesos,
as the case may be. We are exposed to foreign exchange rate fluctuations as the
financial results of foreign subsidiaries are translated into U.S. dollars in
consolidation. Foreign exchange rate fluctuations did not have a material
impact on our financial results in the three-month or nine-month periods ended
September 30, 2002 and 2001.

The following are our contractual obligations as of September 30, 2002
associated with our capital and operating lease obligations:

|                                              |                                    |   |                        |        |        |   |           |       |       |   |         |       |           |   |       |       |  |   |       |       | 
|--------------------------------------------- | ---------------------------------- | - | ---------------------- | ------ | ------ | - | --------- | ----- | ----- | - | ------- | ----- | --------- | - | ----- | ----- |  | - | ----- | ----- | 
|                                              |                                    |   | Payments Due by Period
|                                              |                                    |   |                       
|                                              |                                    |   |                        |        |        |   | Less Than |       | 1-3   |   | 4-5     |       | More Than
|                                              |                                    |   | Total                  |        | 1 Year |   | Years     |       | Years |   | 5 Years
|                                              |                                    |   |                        |        |        |   |           |       |       |   |        
|                                              |                                    |   | (in thousands)        
|Capital lease obligations, including interest |                                    | $ | 192                    |        |        | $ | 152       |       |       | $ | 38      |       |           | $ | 2     |       |  | $ |      |      
|Operating leases                              |                                    |   | 14,016                 |        |        |   | 1,858     |       |       |   | 3,745   |       |           |   | 3,349 |       |  |   | 5,064 |      
|                                              |                                    |   |                        |        |        |   |           |       |       |   |         |       |           |   |       |       |  |   |       |      
|                                              | Total contractual cash obligations |   | $                      | 14,208 |        |   | $         | 2,010 |       |   | $       | 3,783 |           |   | $     | 3,351 |  |   | $     | 5,064 | 
|                                              |                                    |   |                        |        |        |   |           |       |       |   |         |       |           |   |       |       |  |   |       |      

Our operating expenditures have been significant since inception. We
currently anticipate that our operating expenses will significantly exceed net
product sales and that net losses and working capital requirements will consume
a material amount of our cash resources. We believe that the balance of our
cash and cash equivalents at September 30, 2002 will be sufficient to meet our
anticipated cash needs for net losses, working capital and capital expenditures
for at least the next 18 months.

In the future, we may require additional funds to support our working
capital requirements or for other purposes and may seek to raise such
additional funds through public or private equity financing or through other
sources, such as credit facilities. We may be unable to obtain adequate or
favorable financing at that time or at all. The sale of additional equity
securities could result in dilution to our shareholders.

Significant Accounting Policies, Estimates and Judgments

Our significant accounting policies are more fully described in Note 1 to
our consolidated financial statements included in our Annual Report on Form
10-K, which was filed with the Securities and Exchange Commission on March 29,
2002. Certain of our accounting policies require the application of significant
judgment by management in selecting the appropriate assumptions for calculating
financial estimates. By their nature, these judgments are subject to an
inherent degree of uncertainty. These judgments are based on historical
experience, terms of existing contracts, commonly accepted industry practices,
information provided by our customers and other assumptions that we believe are
reasonable under the circumstances. Our estimates and assumptions are reviewed
periodically and the effects of revisions are reflected in the consolidated
financial statements in the period they are determined to be necessary. Actual
results may differ from these estimates under different assumptions or
conditions. Our significant accounting policies and estimates include:

Revenue Recognition

We sell our product through independent, third-party distributors. Our
contracts with those distributors provide no price protection or product-return
rights. We recognize revenue from product sales, net of sales allowances, when
product is delivered to our distributors and all of our significant obligations
have been satisfied, unless acceptance provisions or other contingencies exist.
If acceptance provisions or contingencies exist, revenue is recognized after
such provisions or contingencies have been satisfied. Sales allowances
represent estimated allowances granted to independent distributors for sales
and marketing support, product warehousing and delivery and information
exchange and are based on a percentage of sales. Sales allowances are accrued
when the related product sales revenues are recognized and are paid to
distributors when the distributors sell the product and report the sales data
to us, usually on a quarterly basis. Actual sales allowances paid may be higher
or lower than the estimate accrued, depending upon the level of service
provided by the distributor. We also record an allowance for warranty claims
based on a percentage of sales, at the time revenues are recognized. The
warranty percentage, which has ranged between one to five percent, is reviewed
periodically and adjusted as necessary, based on our experience and future
estimations.

-12-



---



##### Table of Contents



Accounts Receivable and Allowance for Doubtful Accounts

Accounts receivable balances are reported net of related deferred revenue
and liabilities for sales allowances payable. In determining the adequacy of
the allowance for doubtful accounts, we consider a number of factors, including
the aging of the accounts receivable portfolio, customer payment trends, the
financial condition of our customers, historical bad debts and current economic
trends. Based upon our analysis of outstanding net accounts receivable at
September 30, 2002, no allowance for doubtful accounts was recorded.

Inventory

Our inventory is valued at the lower of cost or market on an average-cost
basis. We regularly review inventory balances to determine whether a write-down
is necessary. We consider various factors in making this determination,
including recent sales history and predicted trends, industry market conditions
and general economic conditions. No inventory write-downs were recorded during
the three months ended September 30, 2002.

Valuation of Property and Equipment

We periodically review the carrying values of our property and equipment
to determine whether such assets have been impaired. An impairment loss must be
recorded pursuant to SFAS No. 144, Accounting for the Impairment or Disposal
of Long-Lived Assets, when the undiscounted net cash flows to be realized from
the use of such assets are less than their carrying value. The determination of
undiscounted net cash flows requires us to make many estimates, projections and
assumptions, including the lives of the assets, future sales and expense
levels, additional capital investments or expenditures necessary to maintain
the assets, industry market trends and general and industry economic
conditions. Based upon our most recent analysis of net cash flows to be
realized from our investments in property and equipment, no impairment loss was
recorded.

We are currently marketing excess laboratory and office space at our
headquarters in Bothell, Washington. If we are successful in finding a
qualified subtenant and negotiating a sublease agreement, the market lease rate
is not likely to cover all of the unamortized costs of leasehold improvements
and equipment related to the subleased space. While it is not possible at this
time to estimate the amount of a shortfall, the write-off of these fixed assets
would likely have a material adverse impact on our results of operations for
the quarter and year in which the charge is recorded. At September 30, 2002,
the estimated net book value of leasehold improvements and equipment in the
space being marketed for sublease was approximately $4.6 million. Changes in
the factors listed above or other factors could result in significantly
different cash flow estimates and an impairment charge.

Recent Accounting Pronouncements

SFAS No. 143  In June 2001, the Financial Accounting Standards Board
(FASB) issued SFAS No. 143, Accounting for Asset Retirement Obligations,
which provides the accounting requirements for retirement obligations
associated with tangible long-lived assets. This statement requires entities to
record the fair value of a liability for an asset retirement obligation in the
period in which it is incurred. This statement will be effective for our 2003
fiscal year, and early adoption is permitted. The adoption of SFAS No. 143 is
not expected to have a material impact on our consolidated results of
operations, financial position or cash flows.

SFAS No. 146  In June 2002, the FASB issued SFAS No. 146, Accounting for
Costs Associated with Exit or Disposal Activities. This statement addresses
financial accounting and reporting for costs associated with exit or disposal
activities and nullifies Emerging Issues Task Force Issue No. 94-3, Liability
Recognition for Certain Employee Termination Benefits and Other Costs to Exit
an Activity (including Certain Costs Incurred in a Restructuring). This
statement requires that a liability for a cost associated with an exit or
disposal activity be recognized at fair value when the liability is incurred.
This statement will be effective for our 2003 fiscal year, and early adoption
is permitted. We are currently assessing the impact of this statement on our
results of operations, financial position and cash flows.

-13-



---



##### Table of Contents






Factors That May Affect Our Business, Future Operating Results and Financial Condition

You should carefully consider the risks described below, together with all
of the other information included in this quarterly report on Form 10-Q. The
risks and uncertainties described below are not the only ones facing our
company. If any of the following risks actually occurs, our business, financial
condition or operating results could be harmed.

We currently depend on a single product and our development and
commercialization of that product may not be successful.

For the immediately foreseeable future we will be dependent on the
successful development and commercialization of one product, Messenger, which
is based on a new technology. While Messenger has been subject to numerous
field tests on a wide variety of crops with favorable results, we have only
recently begun sales of Messenger, and Messenger could prove to be commercially
unsuccessful. Messenger may not prove effective or economically viable for all
crops or markets. In addition, because Messenger has not been put to widespread
commercial use over significant periods of time, no assurance can be given that
adverse consequences might not result from the use of Messenger, such as soil
or other environmental degradation, the development of negative effects on
animals or plants or reduced benefits in terms of crop yield or protection.

The markets for Messenger and other harpin-based products we may develop
are unproven. Messenger may not gain commercial acceptance or success. If we
are unable to successfully achieve broad market acceptance of Messenger, we may
not be able to generate enough product revenues in the future to achieve
profitability. A variety of factors will determine the success of our market
development and commercialization efforts and the rate and extent of market
acceptance of Messenger, including our ability to implement and maintain an
appropriate pricing policy for Messenger, general economic conditions in
agricultural markets, including commodity prices, climatic conditions and the
extent that growers, regulatory authorities and the public accept new
agricultural practices and products developed through biotechnology.

Inability to develop adequate sales and marketing capabilities could prevent us
from successfully commercializing Messenger and other products we may develop.

We currently have limited sales and marketing experience and capabilities.
Our internal sales and marketing staff consists primarily of sales and
marketing specialists and field development specialists who are trained to
educate growers and independent distributors on the uses and benefits of
Messenger. We will need to further develop our sales, marketing and field
development capabilities in order to enhance our commercialization efforts,
which will involve substantial costs. These specialists require a high level of
technical expertise and knowledge regarding Messengers capabilities and other
plant protection and yield enhancement products and techniques. We cannot
assure you that our specialists and other members of our sales and marketing
team will successfully compete against the sales and marketing operations of
our current and future competitors that may have more established relationships
with distributors, retailers and growers. Failure to recruit, train and retain
important sales and marketing personnel, such as our sales and marketing
specialists and field development specialists, or the inability of new sales
and marketing personnel to effectively market and sell Messenger and other
products we may develop, could impair our ability to gain market acceptance of
our products and cause our sales to suffer.

We have a history of losses since inception, we expect to continue to incur
losses and we may not achieve or sustain profitability.

We have incurred operating losses in each quarter since inception and we
expect to continue to incur further operating losses for the foreseeable
future. From our inception in July 1994 to September 30, 2002, we have
accumulated a deficit of $77.2 million. For the years ended December 31, 2001
and 2000, we had net losses of
$23.7 million and $15.7 million, respectively. For the nine months ended
September 30, 2002, we had a net loss of $14.9 million. To date, our revenues
have been limited. We expect our future revenues to come primarily from the
sale of Messenger, and these sales are highly uncertain. For example, there
were no sales of Messenger in the fourth quarter of 2001, sales in the third
quarter of this year were down by 90% from the same quarter last year and we
expect sales in the fourth quarter of 2002 to be minor.

Moreover, some of our major distributors in the United States,
particularly in our Southern region, currently hold significant inventories of
Messenger. In 2000, we shipped approximately 453,000 ounces of Messenger to our
U.S. distributors. We estimate that approximately 66,000 ounces were sold by
our distributors to growers in 2000

-14-



---



##### Table of Contents



and approximately 387,000 ounces remained in distributors inventories at
December 31, 2000. In 2001, we shipped approximately 1,225,000 ounces of
Messenger to our U.S. distributors. We estimate that approximately 596,000
ounces were sold by our distributors to growers in 2001 and approximately
1,016,000 ounces remained in distributors inventories at December 31, 2001. In
the first nine months of 2002, we shipped approximately 477,000 ounces of
Messenger to our U.S. distributors. We estimate that approximately 611,000
ounces were sold by our distributors to growers in the first nine months of
2002 and that approximately 882,000 ounces remained in distributors
inventories at September 30, 2002. We do not expect distributors that hold
significant inventories of Messenger to place additional orders for Messenger
until their current inventories are reduced, which will adversely affect our
sales and results of operations. We expect to continue to devote substantial
resources to maintaining and operating our manufacturing facility and to
funding our research and development and sales and marketing activities in the
United States and foreign countries. As a result, we will need to generate
significant revenues to achieve and maintain profitability. We may never
generate profits, and if we do become profitable, we may be unable to sustain
or increase profitability on a quarterly or annual basis.

We may have to reduce operations if we are unable to meet our funding
requirements.

We will require substantial additional funding to continue our research
and development activities, maintain and operate our manufacturing facilities
and commercialize worldwide Messenger and any other products we may develop. If
we are unable to generate sufficient cash flow from operations, or obtain funds
through additional financing, we may have to delay, curtail or eliminate some
or all of our research and development, field testing, marketing or
manufacturing programs. For example, we reduced our workforce by 23% in May
2002, significantly curtailing our European operations. We believe that our
existing capital resources will be sufficient to support our operations for at
least the next 18 months. Our future capital requirements will depend on the
success of our operations.

If our capital requirements vary from our current plans, we may require
additional financing sooner than we anticipate. Financing may be unavailable to
us when needed or on acceptable terms.

If our ongoing or future field trials are unsuccessful, we may be unable to
achieve market acceptance or obtain regulatory approval of our current product
or any other products we may develop.

The successful completion of multiple field trials in domestic and foreign
locations on a wide variety of crops is critical to the success of our product
development and marketing efforts. If our ongoing or future field trials are
unsuccessful or produce inconsistent results or adverse side effects, or if we
are unable to collect reliable data, regulatory approval of our current product
or any other products we may develop could be delayed or withheld or we may be
unable to achieve market acceptance of these products. Although we have
conducted successful field trials on a broad range of crops, we cannot be
certain that additional field trials conducted on a greater number of acres, or
on crops for which we have not yet conducted field trials, will be successful.
Moreover, the results of our ongoing and future field trials are subject to a
number of conditions beyond our control, including weather-related events such
as droughts and floods, severe heat and frost, hail, tornadoes and hurricanes.
Generally, we pay third parties, such as growers, consultants and universities,
to conduct our field trials for us. Incompatible crop treatment practices or
misapplication of the product by third parties could interfere with the success
of our field trials.

We are at an early stage of development and are subject to the risks of a new
enterprise and the commercialization of a new technology.

We began our operations in 1994 and began the marketing and sale of our
first product, Messenger, in the third quarter of 2000. Our early stage of
development, the newness of our technology and the uncertain nature of the
market in which we compete make it difficult to assess our prospects or predict
our future operating results. We are subject to risks and uncertainties
frequently encountered in the establishment of a new business enterprise,
particularly in the rapidly changing market for plant protection and yield
enhancement products. These risks include our inability to transition from a
company with a research focus to a company capable of supporting commercial
activities, including manufacturing, quality control and assurance, regulatory
approval and compliance, marketing, sales, distribution and customer service.
Our inability to adequately address these risks could cause us to be
unprofitable or to cease operations.

-15-



---



##### Table of Contents



Actual storage conditions of Messenger may cause it to degrade more rapidly
than we anticipate, which could adversely affect market acceptance of Messenger
or our results of operations.

Messenger is currently being stored in large quantities under various
conditions by us and by our distributors in the United States. We have
conducted laboratory studies that indicate Messenger is stable for at least two
years under our recommended storage conditions. No assurance can be given,
however, that actual storage conditions will not cause Messengers quality to
degrade over a shorter time period. If this were to occur, we may have to
record inventory write-downs or, if required or we decide to do so, replace
product held by distributors or growers, which could adversely impact the
market acceptance of Messenger or our results of operations.

We may be unable to establish or maintain successful relationships with
independent distributors and retailers, which could adversely affect our sales.

We intend to rely on independent distributors and retailers of
agri-chemicals to distribute and assist with the marketing and sale of
Messenger and any other products we may develop. We have engaged several
independent distributors and retailers for the distribution and sale of
Messenger. Our future revenue growth will depend in large part on our success
in establishing and maintaining these sales and distribution channels. We are
in the early stages of developing our distribution network and we may be unable
to establish or maintain these relationships in a timely or cost-effective
manner. Moreover, we cannot assure you that the distributors and retailers on
which we rely will focus adequate resources on selling these products or will
be successful in selling them. Many of our potential distributors and retailers
are in the business of distributing and sometimes manufacturing other, possibly
competing, plant protection and yield enhancement products and may perceive
Messenger as a threat to various product lines currently being manufactured or
distributed by them. In addition, the distributors may earn higher margins by
selling competing products or combinations of competing products. If we are
unable to establish or maintain successful relationships with independent
distributors and retailers, we will need to further develop our own
distribution capabilities, which would be expensive and time-consuming and the
success of which would be uncertain.

Three of our distributors accounted for an aggregate of 33% of our net
sales revenue for the nine months ended September 30, 2002. One of these
distributors, AG Rx, Inc., accounted for $195,000 (12%) of our net sales
revenue. Helena Chemical Company accounted for $191,200 (11%) of our net sales
revenue and Triangle Chemical Company, Inc. accounted for $164,700 (10%) of our
net sales revenue. If any of these distributors, or any other distributor which
purchases a significant amount of our products, were to discontinue purchasing
our products at any time, our sales would be adversely affected. In addition,
the failure of any of these distributors, or of any other distributor to which
we extend a significant amount of credit, to pay its account, now or in the
future, may harm our operating results.

Inability to obtain regulatory approvals, or to comply with ongoing and
changing regulatory requirements, could delay or prevent sales of Messenger or
any other products we may develop.

The field testing, manufacture, sale and use of plant protection and yield
enhancement products, including Messenger and any other products we may
develop, are extensively regulated by the EPA and state, local and foreign
governmental authorities. These regulations substantially increase the cost and
time associated with bringing Messenger and any other products we may develop
to market. If we do not receive the necessary governmental approvals to test,
manufacture and market these products, or if the regulatory authorities revoke
our approvals or grant them subject to restrictions on their use, we may be
unable to sell these products and our business may fail.

In April 2000, we received conditional approval from the EPA to market and
sell our first product, Messenger, in the United States. In April 2002, the EPA
determined that all conditions for registration had been satisfied and
converted the conditional registration of Messenger to unconditional. We are
also required to obtain regulatory approval from certain state and foreign
regulatory authorities before we market Messenger in those jurisdictions.
Certain of these jurisdictions may apply different criteria than the EPA in
connection with their approval processes. Although we are authorized to sell
Messenger in 48 states on virtually all crops for crop production and disease
management and in California on strawberries, grapes and fruiting vegetables,
such as tomatoes and peppers, for disease management, we have not received
approval for Messenger in Colorado or for use on other crops in California. We
have also received authorization to sell Messenger in 26 foreign countries,
including China, Germany, Mexico and six Central American countries. Our
registration in China is temporary and limited to the sale of Messenger for use
on several crops, including tomatoes, peppers, rice, cotton, tobacco and rape
seed.

-16-



---



##### Table of Contents



If we significantly modify Messengers design as a result of our ongoing
research and development projects, additional EPA and other regulatory
approvals may be required. Moreover, we cannot assure you that we will be able
to obtain approval for marketing additional harpin-based products or product
extensions that we may develop. For example, while the EPA has in place a
registration procedure for products such as Messenger that is streamlined in
comparison to the registration procedure for chemical pesticides, there can be
no assurance that all of our products or product extensions will be eligible
for the streamlined procedure or that the EPA will not impose additional
requirements that could make the procedure more time-consuming and costly for
any future products we may develop.

Even if we obtain all necessary regulatory approvals to market and sell
Messenger and any other products we may develop, Messenger and these other
products will be subject to continuing review and extensive regulatory
requirements. The EPA, as well as state and foreign governmental authorities,
could withdraw a previously approved product from the market upon discovery of
new information, including an inability to comply with regulatory requirements,
the occurrence of unanticipated problems with the product or for other reasons.
In addition, federal, state and foreign regulations relating to crop protection
products developed through biotechnology are subject to public concerns and
political circumstances and, as a result, regulations have changed and may
change substantially in the future. These changes may result in limitations on
the manufacturing, marketing or use of Messenger or any other products we may
develop and commercialize.

Inability to satisfy the conditions of our California registration for
strawberries could limit or prevent sales of Messenger in that state.

Our registration to sell Messenger in California for use on strawberries
for disease management is conditioned on the requirement that we submit data
from several additional studies within various required timeframes ending on
March 31, 2003. There are no conditions on our registration to sell Messenger
in California for use on fruiting vegetables and grapes for disease management.
As required by the California registration for use on strawberries, in April
2001 we submitted to the California Department of Pesticide Regulation the data
required by the EPA as a condition of federal registration. We submitted the
results of six additional strawberry field trials in December 2001, other
information in March 2002 and the results of another six strawberry field
trials in July 2002. We will submit the results of additional studies to the
CDPR at various times in 2002 and 2003, in accordance with the conditions of
our registration. If we are unable to conduct the studies required by the CDPR
in a timely manner, or if the results of the studies are unacceptable to the
CDPR, they may not allow the continued use of Messenger on strawberries in
California or they may impose limitations on this use of Messenger, which could
have a negative impact on our sales. Because EPA and state approvals are
required for commercial sales of Messenger, the loss of any of these approvals
for any reason would prevent further sales of Messenger in the affected state
or nationwide.

The high level of competition in our market may result in price reductions,
reduced margins or the inability of our products to achieve market acceptance.

The market for plant protection and yield enhancement products is
intensely competitive, rapidly changing and undergoing consolidation. We may be
unable to compete successfully against our current or future competitors, which
may result in price reductions, reduced margins or the inability to achieve
market acceptance of Messenger or any other products we may develop.

Many companies are engaged in developing plant protection and yield
enhancement products. Our competitors include major international agri-chemical
companies, specialized biotechnology companies and research and academic
institutions. Many of these organizations have significantly more capital,
research and development, regulatory, manufacturing, distribution, sales,
marketing, human and other resources than we do. As a result, they may be able
to devote greater resources to the development, manufacture, promotion or sale
of their products, receive greater resources and support from independent
distributors, initiate or withstand substantial price competition or take
advantage of acquisition or other opportunities more readily. Furthermore,
these large agri-chemical companies have a more diversified product offering
than we do, which may give them an advantage in meeting customer needs by
enabling them to offer integrated solutions to plant protection and yield
enhancement.

International expansion will subject us to risks associated with international
operations, which could adversely affect both our domestic and international
operations.

Our success depends in part on our ability to expand internationally as we
obtain regulatory approvals to market and sell Messenger and any other products
we may develop in other countries. We have been conducting field trials

-17-



---



##### Table of Contents



in several international locations, and we have personnel in Europe and
Mexico to develop operations in those regions. International expansion of our
operations could impose substantial burdens on our resources, divert
managements attention from domestic operations or otherwise adversely affect
our business. Furthermore, international operations are subject to several
inherent risks, especially different regulatory requirements and reduced
protection of intellectual property rights, that could adversely affect our
ability to compete in international markets and could have a negative effect on
our operating results.

Inability to protect our patents and proprietary rights in the United States
and foreign countries could limit our ability to compete effectively since our
competitors may take advantage of our patents or proprietary rights.

Our success depends on our ability to obtain and maintain patent and other
proprietary-right protection for our technology and products in the United
States and other countries. If we are unable to obtain or maintain these
protections, we may not be able to prevent third parties from using our
proprietary rights. We also rely on trade secrets, proprietary know-how and
continuing technological innovation to remain competitive. We have taken
measures to protect our trade secrets and know-how, including the use of
confidentiality agreements with our employees, consultants and advisors. It is
possible that these agreements may be breached and that any remedies for breach
will not make us whole. We generally control and limit access to, and the
distribution of, our product documentation and other proprietary information.
Despite our efforts to protect these proprietary rights, unauthorized parties
may copy aspects of our products or obtain and use information that we regard
as proprietary. We also cannot guarantee that other parties will not
independently develop our know-how or otherwise obtain access to our
technology.

The laws of some foreign countries do not protect proprietary rights to
the same extent as the laws of the United States, and many companies have
encountered significant problems and incurred significant costs in protecting
their proprietary rights in these foreign countries.

Patent law is still evolving with respect to the scope and enforceability
of claims in the fields in which we operate. We are like many biotechnology
companies in that our patent protection is highly uncertain and involves
complex legal and technical questions for which legal principles are not firmly
established. Our patents and those patents for which we have license rights may
be challenged, narrowed, invalidated or circumvented. In addition, our issued
patents may not contain claims sufficiently broad to protect us against third
parties with similar technologies or products, or provide us with any
competitive advantage. We are not certain that our pending patent applications
will be issued. Moreover, our competitors could challenge or circumvent our
patents or pending patent applications.

The U.S. Patent and Trademark Office and the courts have not established a
consistent policy regarding the breadth of claims allowed in biotechnology
patents. The allowance of broader claims may increase the incidence and cost of
patent interference proceedings and the risk of infringement litigation. On the
other hand, the allowance of narrower claims may limit the value of our
proprietary rights.

Other companies may claim that we infringe their intellectual property or
proprietary rights, which could cause us to incur significant expenses or be
prevented from selling Messenger or any other products we may develop.

Our success depends on our ability to operate without infringing the
patents and proprietary rights of third parties. Product development is
inherently uncertain in a rapidly evolving technological environment in which
there may be numerous patent applications pending, many of which are
confidential when filed, with regard to similar technologies. Future patents
issued to third parties may contain claims that conflict with our patents.
Although we believe that Messenger does not infringe the proprietary rights of
any third parties, third parties could assert infringement claims against us in
the future. Any litigation or interference proceedings, regardless of their
merit or outcome, would probably be costly and require significant time and
attention of our key management and technical personnel. Litigation or
interference proceedings could also force us to:



| |  |  | stop or delay selling, manufacturing or using products that
incorporate the challenged intellectual property;
| | - |  | -------------------------------------------------------------------------------------------------------------
|
| |  |  | pay damages; or                                                                                              
|
| |  |  | enter into licensing or royalty agreements that may be unavailable on acceptable terms.                      

-18-



---



##### Table of Contents



If we do not adequately distinguish Messenger from products that genetically
modify plants and certain other products, public concerns over those products
could negatively impact market acceptance of Messenger.

Claims that genetically engineered products are unsafe for consumption or
pose a danger to the environment have led to public concerns and negative
public attitudes, particularly in Europe. We intend to distinguish Messenger
and harpin-related technologies from products that genetically modify plants.
While our technology does involve genetic modification in the process of
manufacturing Messenger, Messenger and harpin-related technologies are
topically applied and do not genetically modify the plants DNA. If the public
or potential customers perceive Messenger as a product that genetically
modifies the plant, Messenger may not gain market acceptance. Similarly,
countries that have imposed more restrictive regulations on products that
genetically modify plants, including Japan and certain members of the European
Union, may perceive Messenger as a product that genetically modifies plants. If
so, regulators in those countries may impose more restrictive regulations on
Messenger, which could delay, limit or impair our ability to market and sell
Messenger in those countries.

We may be exposed to product liability claims, which could adversely affect our
operations.

We may be held liable or incur costs to settle product liability claims if
any products we may develop, or any products that use or incorporate any of our
technologies, cause injury or are found unsuitable during product testing,
manufacturing, marketing, sale or use. These risks exist even with respect to
any products that have received, or may in the future receive, regulatory
approval, registration or clearance for commercial use. We cannot guarantee
that we will be able to avoid product liability exposure.

We currently maintain product liability insurance at levels we believe are
sufficient and consistent with industry standards for companies at our stage of
development. We cannot guarantee that our product liability insurance is
adequate, and, at any time, it is possible that such insurance coverage may not
be available on commercially reasonable terms or at all. A product liability
claim could result in liability to us greater than our assets and insurance
coverage. Moreover, even if we have adequate insurance coverage, product
liability claims or recalls could result in negative publicity or force us to
devote significant time and attention to matters other than those that arise in
the normal course of business.

Rapid changes in technology could render our current product or any other
products we may develop unmarketable or obsolete.

We are engaged in an industry characterized by extensive research efforts
and rapid technological development. Our competitors, many of which have
substantially greater technological and financial resources than we do, may
develop plant protection and yield enhancement technologies and products that
are more effective than ours or that render our technology and products
obsolete or uncompetitive. To be successful, we will need to continually
enhance Messenger and any other products we may develop and to design, develop
and market new products that keep pace with new technological and industry
developments.

Our product development efforts, which are based on an innovative technology
that is commercially unproven, may not be successful.

Our harpin and harpin-related technology is new, in an early stage of
development and commercially unproven. It may take years and significant
capital investment to develop viable enhancements of Messenger or any new
products we may develop based on our harpin and harpin-related technology.
Risks inherent in the development of products based on innovative technologies
include the possibility that:



| |  |  | new products or product enhancements will be uneconomical to market
or will be difficult to produce on a large scale;
| | - |  | ---------------------------------------------------------------------------------------------------------------------
|
| |  |  | proprietary rights of third parties will prevent us from marketing products; and                                     
|
| |  |  | third parties will market superior or equivalent products or will market their products first.                       

-19-



---



##### Table of Contents



Inability to comply with regulations applicable to our facilities and
procedures could delay, limit or prevent our research and development or
manufacturing activities.

Our research and development and manufacturing facilities and procedures
are subject to continual review and periodic inspection. To comply with the
regulations applicable to these facilities and procedures, we must spend funds,
time and effort in the areas of production, safety and quality control and
assurance to help ensure full technical compliance. If the EPA or another
regulator determines that we are not in compliance, regulatory approval of
Messenger or any other products we may develop could be revoked, delayed or
withheld or we may be required to limit or cease our research and development
or manufacturing activities or pay a monetary fine. If we were required to
limit or cease our research and development activities, our ability to develop
new products would be
impaired. In addition, if we were required to limit or cease our
manufacturing activities, our ability to produce Messenger in commercial
quantities would be impaired or prohibited, which could have an adverse effect
on our sales.

Inability to produce a high quality product could impair our business.

To be successful, we will have to manufacture Messenger in large
quantities at acceptable costs while also preserving high product quality. If
we cannot maintain high product quality on a large scale, we may be unable to
achieve market acceptance of our product and our sales would likely suffer.
Moreover, we do not have back-up manufacturing systems and, as a result, any
failure of any component required in the manufacturing process could delay or
impair our ability to manufacture Messenger in the quantities that we may
require.

We intend to continue to make changes to our manufacturing processes and
facilities in order to improve the efficiency and quality of our manufacturing
activities. We cannot guarantee that we will be successful in this regard or
that the changes we make will improve our manufacturing activities. We may
encounter difficulties in the production of our current product or any future
products we may develop, including problems involving manufacturing processes
or yields, packaging, distribution, storage, quality control and assurance,
shortages of qualified personnel or compliance with regulatory requirements.
Even if we are successful in developing our manufacturing capability and
processes, there can be no assurance that we will satisfy the requirements of
our distributors or customers.

If third-party manufacturers fail to adequately perform, we could be unable to
meet demand and our revenues could be impaired.

We currently depend on independent manufacturers to perform certain
portions of our production process. We intend to engage additional third-party
manufacturers as necessary to perform these processes. Any failure or delay in
the ability of our current or any future manufacturers to provide us with
material they produce could adversely affect our ability to produce Messenger
in the quantities necessary to satisfy the requirements of our distributors or
customers, or could increase our costs associated with obtaining such
materials. In addition, the time and resources that our current or future
third-party manufacturers devote to our business are not within our control. We
cannot ensure that our current or future third-party manufacturers will perform
their obligations to meet our quality standards, that we will derive cost
savings or other benefits from our relationships with them or that we will be
able to maintain a satisfactory relationship with them on terms acceptable to
us. Moreover, these manufacturers may support products that compete directly or
indirectly with ours, or offer similar or greater support to our competitors.
If any of these events were to occur, our business and operations could be
adversely affected.

Inability to address strain on our resources caused by growth could result in
ineffective management of our business.

As we add manufacturing, marketing, sales, field development and other
personnel, both domestically and internationally, during the commercialization
of Messenger, and expand our manufacturing and research and development
capabilities, we expect that our operating expenses and capital requirements
will increase. Our ability to manage growth effectively requires us to continue
to expend funds to improve our operational, financial and management controls,
reporting systems and procedures. In addition, we must effectively expand,
train and manage our employee base. We will be unable to effectively manage our
business if we are unable to timely and successfully alleviate the strain on
our resources caused by growth in our business, which could adversely affect
our operating results.

-20-



---



##### Table of Contents



Inability to retain our key employees or other skilled managerial or technical
personnel could impair our ability to maintain or expand our business.

We are highly dependent on the efforts and abilities of our current key
managerial and technical personnel, particularly Dr. Rhett R. Atkins, our
President and Chief Executive Officer; Bradley Powell, our Chief Financial
Officer; and Dr. Zhongmin Wei, our Chief Scientific Officer and Vice President
of Research. Our success will depend in part on retaining the services of Drs.
Atkins and Wei and Mr. Powell and our other existing key management and
technical personnel and on attracting and retaining new, highly qualified
personnel.

Inability to retain our existing key management or technical personnel or
to attract additional qualified personnel could, among other things, delay our
sales, marketing and research and development efforts. Moreover, in our field,
competition for qualified management and technical personnel is intense and
many of the companies with which we compete for experienced personnel have
greater financial and other resources than we do. As a result, we may be unable
to recruit, train and retain sufficient qualified personnel.

Our operating results are likely to fluctuate, resulting in an unpredictable
level of sales and earnings and possibly in a decrease in our stock price.

Our operating results for a particular quarter or year are likely to
fluctuate, which could result in uncertainty surrounding our level of sales and
earnings and possibly result in a decrease in our stock price. For example,
there were no sales of Messenger in the fourth quarter of 2001. Numerous other
factors will contribute to the unpredictability of our operating results. In
particular, our sales are expected to be highly seasonal. Sales of plant
protection and yield enhancement products are dependent on planting and growing
seasons, climatic conditions, economic and other variables, which we expect to
result in substantial fluctuations in our quarterly sales and earnings. For
example, weather-related events such as droughts and floods, severe heat and
frost, hail, tornadoes and hurricanes could decrease demand for our product and
any future products we may develop, and have an adverse impact on our operating
results from quarter to quarter. In addition, most of our expenses, such as
employee compensation and lease payments for facilities and equipment, are
relatively fixed. Our expense levels are based, in part, on our expectations
regarding future sales. As a result, any shortfall in sales relative to our
expectations could cause significant changes in our operating results from
quarter to quarter. Other factors may also contribute to the unpredictability
of our operating results, including the amount of Messenger carried in
inventory by independent distributors and retailers, the size and timing of
significant customer transactions, the delay or deferral of customer use of our
product and the fiscal or quarterly budget cycles of our customers. For
example, customers may purchase large quantities of our product in a particular
quarter to store and use over long periods of time, or time their purchases to
coincide with the availability of capital, which may cause significant
fluctuations in our operating results for a particular quarter or year.




Item 3. Quantitative and Qualitative Disclosures About Market Risk

We do not currently hold any derivative instruments, and we do not engage
in hedging activities. Also, we do not have any outstanding variable rate debt
and currently do not enter into any material transactions denominated in
foreign currency. Therefore, our direct exposure to interest rate and foreign
exchange rate fluctuation is currently not material to our results of
operations. We believe that the market risk arising from the financial
instruments we hold is not material.




Item 4. Controls and Procedures

Within the 90 days prior to the date of this report, we carried out an
evaluation, under the supervision and with the participation of management,
including our President and Chief Executive Officer and our Chief Financial
Officer, of the effectiveness of the design and operation of our disclosure
controls and procedures (as defined in Rule 13a-14 under the Securities
Exchange Act of 1934). Based upon that evaluation, our President and Chief
Executive Officer and our Chief Financial Officer concluded that our disclosure
controls and procedures are effective. There have been no significant changes
in our internal controls or in other factors which could significantly affect
internal controls subsequent to the date we carried out our evaluation,
including any corrective actions with regard to significant deficiencies and
material weaknesses.

-21-



---



##### Table of Contents






PART II  OTHER INFORMATION




Item 2. Changes in Securities and Use of Proceeds

On September 26, 2000, the SEC declared effective our Registration
Statement on Form S-1, as amended (Registration No. 333-41028), as filed with
the SEC in connection with our initial public offering. Proceeds to EDEN, after
accounting for $7.0 million in underwriting discounts and commissions and
approximately $1.6 million in other expenses of the offering, were
approximately $91.5 million.

To date, of the net offering proceeds, we have used approximately $18.3
million to expand and enhance our manufacturing, research and development and
administration facilities, and approximately $39.2 million for working capital
and general corporate purposes. The remaining portion of the net offering
proceeds has been invested in cash equivalent investments. Our use of the
proceeds from the offering does not represent a material change in the use of
proceeds described in the prospectus included as part of the Registration
Statement.




Item 6. Exhibits

The following exhibits are being filed as part of this quarterly report on
Form 10-Q.

(a)  Exhibits.

|        |  |                                                                                                                        
|------- |  | -----------------------------------------------------------------------------------------------------------------------
|Exhibit |  |                                                                                                                        
|Number  |  | Description                                                                                                            
|        |  |                                                                                                                        
|99.1    |  | Certification Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant
to Section 906 of the Sarbanes-Oxley Act of 2002.
|99.2    |  | Certification Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant
to Section 906 of the Sarbanes-Oxley Act of 2002.




SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.

|                       |                                                       |                      
|---------------------- | ----------------------------------------------------- | ---------------------
|                       | EDEN BIOSCIENCE CORPORATION                          
|                      
|Date: November 7, 2002 |                                                       |                      
|                      
|                       | By:                                                   | /s/   Rhett R. Atkins
|                       |                                                      
|                       | Rhett R. Atkins
Chief Executive Officer and President



| |                                                                                                      |                        
| | ---------------------------------------------------------------------------------------------------- | -----------------------
| | By:                                                                                                  | /s/   Bradley S. Powell
| |                                                                                                     
| | Bradley S. Powell
Chief Financial Officer and Secretary
(principal financial and accounting officer)

-22-



---



##### Table of Contents






CHIEF EXECUTIVE OFFICER CERTIFICATION

I, Rhett R. Atkins, President and Chief Executive Officer of EDEN Bioscience
Corporation, certify that:

1. I have reviewed this quarterly report on Form 10-Q of EDEN Bioscience
Corporation;

2. Based on my knowledge, this quarterly report does not contain any untrue
statement of a material fact or omit to state a material fact necessary to make
the statements made, in light of the circumstances under which such statements
were made, not misleading with respect to the period covered by this quarterly
report;

3. Based on my knowledge, the financial statements, and other financial
information included in this quarterly report, fairly present in all material
respects the financial condition, results of operations and cash flows of the
registrant as of, and for, the periods presented in this quarterly report;

4. The registrants other certifying officers and I are responsible for
establishing and maintaining disclosure controls and procedures (as defined in
Exchange Act Rules 13a-14 and 15d-14) for the registrant and we have;

a) designed such disclosure controls and procedures to ensure that material
information relating to the registrant, including its consolidated
subsidiaries, is made known to us by others within those entities, particularly
during the period in which this quarterly report is being prepared;

b) evaluated the effectiveness of the registrants disclosure controls and
procedures as of a date within 90 days prior to the filing date of this
quarterly report (the Evaluation Date); and

c) presented in this quarterly report our conclusions about the effectiveness
of the disclosure controls and procedures based on our evaluation as of the
Evaluation Date;

5. The registrants other certifying officers and I have disclosed, based on
our most recent evaluation, to the registrants auditors and the audit
committee of registrants board of directors (or persons performing the
equivalent function):

a) all significant deficiencies in the design or operation of internal controls
which could adversely affect the registrants ability to record, process,
summarize and report financial data and have identified for the registrants
auditors any material weaknesses in internal controls; and

b) any fraud, whether or not material, that involves management or other
employees who have a significant role in the registrants internal controls;
and

6. The registrants other certifying officers and I have indicated in this
quarterly report whether or not there were significant changes in internal
controls or in other factors that could significantly affect internal controls
subsequent to the date of our most recent evaluation, including any corrective
actions with regard to significant deficiencies and material weaknesses.

|                       |  |                                                      
|---------------------- |  | -----------------------------------------------------
|Date: November 7, 2002 |  | /s/   Rhett R. Atkins                                
|                       |  |                                                      
|                       |  | Rhett R. Atkins
President and Chief Executive Officer

-23-



---



##### Table of Contents






CHIEF FINANCIAL OFFICER CERTIFICATION

I, Bradley S. Powell, Chief Financial Officer of EDEN Bioscience Corporation,
certify that:

1. I have reviewed this quarterly report on Form 10-Q of EDEN Bioscience
Corporation;

2. Based on my knowledge, this quarterly report does not contain any untrue
statement of a material fact or omit to state a material fact necessary to make
the statements made, in light of the circumstances under which such statements
were made, not misleading with respect to the period covered by this quarterly
report;

3. Based on my knowledge, the financial statements, and other financial
information included in this quarterly report, fairly present in all material
respects the financial condition, results of operations and cash flows of the
registrant as of, and for, the periods presented in this quarterly report;

4. The registrants other certifying officers and I are responsible for
establishing and maintaining disclosure controls and procedures (as defined in
Exchange Act Rules 13a-14 and 15d-14) for the registrant and we have;

a) designed such disclosure controls and procedures to ensure that material
information relating to the registrant, including its consolidated
subsidiaries, is made known to us by others within those entities, particularly
during the period in which this quarterly report is being prepared;

b) evaluated the effectiveness of the registrants disclosure controls and
procedures as of a date within 90 days prior to the filing date of this
quarterly report (the Evaluation Date); and

c) presented in this quarterly report our conclusions about the effectiveness
of the disclosure controls and procedures based on our evaluation as of the
Evaluation Date;

5. The registrants other certifying officers and I have disclosed, based on
our most recent evaluation, to the registrants auditors and the audit
committee of registrants board of directors (or persons performing the
equivalent function):

a) all significant deficiencies in the design or operation of internal controls
which could adversely affect the registrants ability to record, process,
summarize and report financial data and have identified for the registrants
auditors any material weaknesses in internal controls; and

b) any fraud, whether or not material, that involves management or other
employees who have a significant role in the registrants internal controls;
and

6. The registrants other certifying officers and I have indicated in this
quarterly report whether or not there were significant changes in internal
controls or in other factors that could significantly affect internal controls
subsequent to the date of our most recent evaluation, including any corrective
actions with regard to significant deficiencies and material weaknesses.

|                       |  |                                          
|---------------------- |  | -----------------------------------------
|Date: November 7, 2002 |  | /s/   Bradley S. Powell                  
|                       |  |                                          
|                       |  | Bradley S. Powell
Chief Financial Officer

-24-